 |
PDF »
October 25, 2004
Cougar Biotechnology Presents CB7630 Phase I Data at Prostate Cancer Foundation Scientific Retreat
Los Angeles, CA, October 25, 2004 - Cougar Biotechnology, Inc, a privately held biotechnology company, announced that results from the Phase I clinical trials of Cougar’s investigational drug, CB7630 (abiraterone acetate) were presented at the Prostate Cancer Foundation Scientific Retreat on October 23rd. The Phase I trials of CB7630 were conducted at the Cancer Research UK Centre for Cancer Therapeutics/Institute of Cancer Research and the Royal Marsden Hospital in the United Kingdom, and the results were published in the British Journal of Cancer in June, 2004.
The presentation, entitled "CB7630 (Abiraterone Acetate): A Novel Targeted Oral Therapy for Hormone-Refractory Prostate Cancer" provided an overview of the clinical data from three dose escalating clinical studies of CB7630 given as a single agent to prostate cancer patients. In the two single dose clinical studies, CB7630 was given to castrate and noncastrate prostate cancer patients at doses ranging from 10 to 500 mg. 4 out of 6 castrate patients treated with a single dose of 500 mg of CB7630 achieved suppression of testosterone to levels less than 0.14 nmol/l. In the multiple dose study, CB7630 was given at a dose of either 500 mg or 800 mg for 12 days to 6 previously treated prostate cancer patients. All patents treated at the 500 mg and 800 mg level experienced suppression of testosterone to castrate levels (less than 2.0 nmol/l). In addition, of the patients treated with 800 mg daily, 2 out of 3 patients had complete suppression of testosterone down to levels that are comparable to those typically seen in patients that are being treated with LHRH agonists (less than 0.7 nmol/l). Treatment with CB7630 was well tolerated with no biochemical or hematological side effects.
"Because the initial clinical trials of CB7630 were performed in Europe, researchers in the US have limited experience with the drug. I am therefore pleased to be able to present the clinical data with this novel prostate cancer drug at a prominent meeting like the Prostate Cancer Foundation Scientific Retreat," said Dr. Arie Belldegrun, MD, FACS, Chairman of the Scientific Advisory Board of Cougar Biotechnology. "We are pleased to have been selected to present our data at this meeting and view it as an important opportunity to build awareness of the drug prior to the advancement of the clinical development of CB7630 that is currently scheduled for next year," added Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology. "We hope to continue our relationship with the Prostate Cancer Foundation throughout the course of the clinical development of CB7630."
About Cougar Biotechnology
Cougar Biotechnology, Inc. is a Los Angeles-based private biotechnology company established to in-license and develop early clinical stage drugs, with a specific focus on the field of oncology.
Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.
Contact
Alan H. Auerbach
Cougar Biotechnology, Inc.
+1 310 443 4209
ahauerbach@cougarbiotechnology.com
| | |
Cougar Biotechnology, Inc.
10990 Wilshire Blvd, Suite 1200
Los Angeles, CA 90024
(310) 943-8040 Main
(310) 943-8059 Fax |
